<DOC>
	<DOCNO>NCT00444795</DOCNO>
	<brief_summary>To monitor use real practice include adverse event efficacy Sutent capsule ( Sunitinib malate )</brief_summary>
	<brief_title>Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene</brief_title>
	<detailed_description>All patient prescribe accord approved indication contract institution</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients diagnose gastrointestinal stromal tumor ( GIST ) disease progression intolerance imatinib mesylate , advance renal cell carcinoma ( aRCC ) include study , patient diagnose unresectable , welldifferentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma . Any patient agree Pfizer company work Pfizer use his/her information exclude . Patients hypersensitivity sunitinib malate component Sutent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>SUTENE</keyword>
	<keyword>post-marketing surveillance</keyword>
	<keyword>GIST</keyword>
	<keyword>RCC</keyword>
	<keyword>Korea</keyword>
</DOC>